Ovid Therapeutics Names Dr. Petra Kaufmann as Chief Medical Officer
Ovid Therapeutics Inc. has appointed Dr. Petra Kaufmann as Chief Medical Officer to oversee clinical, medical, and regulatory strategy for its brain disorder therapies. Dr. Kaufmann brings experience from Vigil Neuroscience, Affinia Therapeutics, Novartis Gene Therapies, and the National Institutes of Health.
Ovid Therapeutics Inc. has appointed Dr. Petra Kaufmann as Chief Medical Officer. Dr. Kaufmann will oversee clinical, medical, and regulatory strategy as Ovid advances its pipeline of therapies for brain disorders. She joins Ovid from Vigil Neuroscience and has previously held senior roles at Affinia Therapeutics, Novartis Gene Therapies, and the National Institutes of Health. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595040-en) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
